We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Universal Blood Test Could Predict Organ Transplant Outcomes with Unprecedented Accuracy

By LabMedica International staff writers
Posted on 19 Jun 2024
Print article
Image: PROMAD is a molecular atlas consisting of more than 12,000 patient samples from around the globe (Photo courtesy of WIMR)
Image: PROMAD is a molecular atlas consisting of more than 12,000 patient samples from around the globe (Photo courtesy of WIMR)

In a landmark study, an interdisciplinary research team from The Westmead Institute for Medical Research (WIMR, NSW, Australia) and the University of Sydney (NSW, Australia) has identified, for the first time, common molecular biomarkers for transplant rejection across major transplanted organs, including hearts, lungs, livers, and kidneys. Their findings suggest that the molecular pathways involved in organ rejection are consistent across these different solid organs. This breakthrough is crucial as it enables the development of strategies aimed at improving the success rates of all types of organ transplants by utilizing machine learning to predict transplant outcomes with remarkable accuracy.

In a collaborative effort, the researchers created the Pan-organ ResOurce for Molecular Allograft Dysfunction (PROMAD), a comprehensive molecular atlas that includes over 12,000 patient samples from across the world. This atlas allows broader access to transplant data that was previously unavailable to many researchers, fostering international cooperation. The creation of this atlas has led to the development of a proof of concept for a universal blood test that can predict the possibility of transplant rejection before it happens, potentially redefining standards in precision medicine and enhancing transplant outcomes globally.

The team is currently advancing this research by trialing a blood test in laboratory settings that could enable physicians to predict and prevent organ rejection. Moreover, their findings provide a foundation for applying these insights to other types of transplantation and different medical conditions. The encouraging outcomes of this research not only highlight the power of international collaboration but also offer new hope to millions awaiting life-saving transplants. Moving forward, the research will expand these discoveries to additional transplant types and further improve the predictive models used in the study.

"This study is a perfect example of how precision medicine can significantly impact clinical practices by integrating global data to benefit individual patients," said Professor Natasha Rogers, Deputy Director of WIMR's Centre for Transplant and Renal Research, and a senior author on the study. The findings of the study were published in Nature Medicine on June 18, 2024.

Related Links:
University of Sydney

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article


Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.